Paper8402913
The human CD46 molecule is a receptor for measles virus (Edmonston strain).
Dörig RE and 3 others. Cell, 1993. Cited by 879 papers, by iCite.
Cite this record
ConductScience Library. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Papers, record 8402913. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8402913
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, CD | Major topic |
| Chromosomes, Human, Pair 1 | Major topic |
| Measles virus | Major topic |
| Membrane Glycoproteins | Major topic |
| Receptors, Virus | Major topic |
| Animals | |
| Base Sequence | |
| CHO Cells | |
| Cell Fusion | |
| Cell Line | |
| Cloning, Molecular | |
| Cricetinae | |
| Humans | |
| Hybrid Cells | |
| Membrane Cofactor Protein | |
| Molecular Sequence Data | |
| Primates | |
| Recombinant Proteins | |
| Rodentia | |
| Species Specificity |
Source PubMed
Cited by471
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 879 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42805178 | Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42805178 | PubMed |
| 42604901 | Protein-Protein Interactions Analyzed by the Fragment Molecular Orbital Method. | Methods Mol Biol | 2026 | https://conductscience.org/library/papers/42604901 | PubMed |
| 42170676 | Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42170676 | PubMed |
| 41631160 | A measles virus encoding a CD19/CD3 bispecific T cell engager shows enhanced preclinical anti-BCP-ALL efficacy without significant toxicity. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41631160 | PubMed |
| 41432296 | CD46 regulates hepatitis B virus entry by modulating cell-surface NTCP levels through cis-interaction. | J Mol Cell Biol | 2026 | https://conductscience.org/library/papers/41432296 | PubMed |
| 41313526 | A comprehensive review redefining viruses as therapeutic agents in cancer treatment. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41313526 | PubMed |
| 41294877 | A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses. | Cells | 2025 | https://conductscience.org/library/papers/41294877 | PubMed |
| 41050431 | Enhanced solid tumor cell targeting by a neoepitope-encoding oncolytic measles virus combined with CAR therapy. | Mol Ther Oncol | 2025 | https://conductscience.org/library/papers/41050431 | PubMed |
| 41031883 | Gut complement system: a new frontier in microbiota-host communication and intestinal homeostasis. | J Clin Invest | 2025 | https://conductscience.org/library/papers/41031883 | PubMed |
| 40697381 | Shaping viral immunotherapy towards cancer-targeted immunological cell death. | Front Oncol | 2025 | https://conductscience.org/library/papers/40697381 | PubMed |
| 40534438 | Exploring the genetic landscape of otosclerosis: current understanding and future perspectives. | Acta Otorhinolaryngol Ital | 2025 | https://conductscience.org/library/papers/40534438 | PubMed |
| 40519165 | Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research. | J Clin Invest | 2025 | https://conductscience.org/library/papers/40519165 | PubMed |
| 40319442 | Current status and prospects of genetically modified porcine-to-human cardiac xenotransplantation. | J Artif Organs | 2025 | https://conductscience.org/library/papers/40319442 | PubMed |
| 40309774 | The multiverse of CD46 and oncologic interactions. | J Clin Invest | 2025 | https://conductscience.org/library/papers/40309774 | PubMed |
| 40303488 | Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer. | Int J Med Sci | 2025 | https://conductscience.org/library/papers/40303488 | PubMed |
| 40083162 | Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy. | Mol Ther | 2025 | https://conductscience.org/library/papers/40083162 | PubMed |
| 39956393 | Syncytial therapeutics: Receptor-specific and direct-to-cytosol biologic drug delivery mediated by measles fusion complex. | J Control Release | 2025 | https://conductscience.org/library/papers/39956393 | PubMed |
| 39698315 | Virus nanotechnology for intratumoural immunotherapy. | Nat Rev Bioeng | 2024 | https://conductscience.org/library/papers/39698315 | PubMed |
| 39698100 | Proteolytic shedding of CD46 from human hepatocytes indicates liver stress. | Heliyon | 2024 | https://conductscience.org/library/papers/39698100 | PubMed |
| 39407352 | The outer membrane protein, OMP71, of Riemerella anatipestifer, mediates adhesion and virulence by binding to CD46 in ducks. | Vet Res | 2024 | https://conductscience.org/library/papers/39407352 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD46 | 4179 | Swiss-Prot's references | https://conductscience.org/library/genes/4179 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8402913
GET https://conductscience.org/api/papers/v1/8402913/cited_by?page=2